The Ministry of Health, through the Pharmacy and Poisons Board (PPB), has issued a warning to members of the public against the off-label use of Semaglutide-containing compounds, popularly marketed under brand names such as Ozempic.
According to the board, the drug is approved for the treatment of adults with type 2 diabetes mellitus that is insufficiently controlled, its unsupervised use by individuals seeking rapid slimming solutions poses serious health dangers.
PPB noted that some of the common side effects associated with the drug include low blood pressure..
Kenyans who suffer adverse reactions have been urged to file complaints through the official PPB pharmacovigilance reporting portals.
